Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name) |
The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. |
|
|
Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name) |
THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary. |
|
|
Lisdexamfetamine |
ESCAs and additional advice in relation to age of patient and CCG |
|
|
|
Lisdexamfetamine#Red |
ESCAs and additional advice in relation to age of patient and CCG |
|
|
|
Lithium carbonate M/R tablet (Priadel) |
Specialist initation only, ESCA |
|
|
|
Lithium citrate liquid priadel |
Specialist initiation only, ESCA |
|
|
|
Lixisenatide (Lyxumia®) |
1st line choice GLP1 for co-prescribing with insulin. RICaD. |
|
|
|
Lizinna |
Umbrella service only |
|
|
|
Loestrin 20 |
Umbrella servide only - puberty induction |
|
|
|
Lofepramine suspension |
Specialist initiation only |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- Next page
- Last page
